DNA flow cytometric and interobserver study of crypt cell atypia in inflammatory bowel disease.
aneuploidy
colorectal cancer
dysplasia
inflammatory bowel disease
Journal
Histopathology
ISSN: 1365-2559
Titre abrégé: Histopathology
Pays: England
ID NLM: 7704136
Informations de publication
Date de publication:
Oct 2019
Oct 2019
Historique:
received:
02
04
2019
accepted:
17
05
2019
pubmed:
22
5
2019
medline:
29
2
2020
entrez:
22
5
2019
Statut:
ppublish
Résumé
The pathological features and diagnostic reliability of crypt cell atypia (CCA) arising in inflammatory bowel disease (IBD) and its clinical significance are unknown. DNA flow cytometry (FCM) was performed on 14 colon biopsies of CCA from seven IBD patients (male-to-female ratio, 5:2; mean age, 53 years; mean IBD duration, 15 years) using paraffin-embedded tissue. Seven gastrointestinal pathologists were asked to diagnose each biopsy as negative for dysplasia (NEG), indefinite for dysplasia (IND), low-grade dysplasia (LGD) or high-grade dysplasia (HGD) by morphology alone, then again with knowledge of FCM results. Aneuploidy was detected in all 14 biopsies, and five of eight biopsies (63%) also showed strong and diffuse nuclear staining for p53 in the areas of CCA. Six (86%) patients developed HGD (n = 5) or adenocarcinoma (n = 1) in the same colonic segment where CCA had been diagnosed within a mean follow-up time of 27 months. No follow-up information was available in the remaining one patient. When diagnoses were grouped as NEG or 'atypical' (including IND, LGD or HGD), the overall agreement rate of 76% (kappa = 0.51) based on morphology alone improved to 90% (kappa = 0.81) with knowledge of FCM results. Even when categorised as NEG or dysplasia (LGD or HGD) with each of the IND diagnoses reclassified into three categories (NEG, LGD or HGD) based on the degree of suspicion for dysplasia, the overall agreement rate of 63% (kappa = 0.25) based on morphology alone improved to 73% (kappa = 0.46) with knowledge of FCM results. However, when grouped as NEG, LGD or HGD, the overall agreement rate was less than 40% (kappa < 0.09) regardless of knowledge of FCM results. The presence of aneuploidy, p53 positivity and development of HGD or adenocarcinoma on follow-up indicate that CCA likely represents a dysplastic lesion (at least LGD) and is a histological marker of neoplastic progression. Although the grading of CCA, largely based on cytological abnormalities, is subject to significant interobserver variability, CCA can be histologically identified and should lead to a recommendation of increased endoscopic surveillance, especially if aneuploidy is detected.
Substances chimiques
DNA
9007-49-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
578-588Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Söderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136; 1561-1567.
Bernstein CN, Blanchard JF, Kliewer E, et al. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer 2001; 91; 854-862.
Jess T, Rungoe C, Peyrin-Biroulet L. Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. Clin. Gastroenterol. Hepatol. 2012; 10; 639-645.
Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn’s disease with colonic involvement. Lancet 1990; 336; 357-359.
Lutgens MW, Oldenburg B, Siersema PD, et al. Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease. Br. J. Cancer 2009; 101; 1671-1675.
Karlén P, Kornfeld D, Broström O, et al. Is colonoscopic surveillance reducing colorectal cancer mortality in ulcerative colitis? A population based case control study. Gut 1998; 42; 711-714.
Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment. Pharmacol. Ther. 2000; 14; 145-153.
Choi CH, Rutter MD, Askari A, et al. Forty-year analysis of colonoscopic surveillance program for neoplasia in ulcerative colitis: an updated overview. Am. J. Gastroenterol. 2015; 110; 1022-1034.
Laine L, Kaltenbach T, Barkun A, et al. SCENIC international consensus statement on surveillance and management of dysplasia in inflammatory bowel disease. Gastrointest. Endosc. 2015; 81; 489-501.
Riddell RH, Goldman H, Ransohoff DF, et al. Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. Hum. Pathol. 1983; 14; 931-968.
Lomo LC, Blount PL, Sanchez CA, et al. Crypt dysplasia with surface maturation: a clinical, pathologic, and molecular study of a Barrett’s esophagus cohort. Am. J. Surg. Pathol. 2006; 30; 423-435.
Shin N, Jo HJ, Kim WK, et al. Gastric pit dysplasia in adjacent gastric mucosa in 414 gastric cancers: prevalence and characteristics. Am. J. Surg. Pathol. 2011; 35; 1021-1029.
Agoston AT, Odze RD. Evidence that gastric pit dysplasia-like atypia is a neoplastic precursor lesion. Hum. Pathol. 2014; 45; 446-455.
Choi WT, Tsai JH, Rabinovitch PS, et al. Diagnosis and risk stratification of Barrett’s dysplasia by flow cytometric DNA analysis of paraffin-embedded tissue. Gut 2018; 67; 1229-1238.
Choi WT, Wen KW, Rabinovitch PS, et al. DNA content analysis of colorectal serrated lesions detects an aneuploid subset of inflammatory bowel disease-associated serrated epithelial change and traditional serrated adenomas. Histopathology 2018; 73; 464-472.
Tsai JH, Rabinovitch PS, Huang D, et al. Association of aneuploidy and flat dysplasia with development of high-grade dysplasia or colorectal cancer in patients with inflammatory bowel disease. Gastroenterology 2017; 153; 1492-1495.
Wen KW, Rabinovitch PS, Huang D, et al. Use of DNA flow cytometry in the diagnosis, risk stratification, and management of gastric epithelial dysplasia. Mod. Pathol. 2018; 31; 1578-1587.
Wen KW, Rabinovitch PS, Wang D, et al. Utility of DNA flow cytometric analysis of paraffin-embedded tissue in the risk stratification and management of ‘indefinite for dysplasia’ in patients with inflammatory bowel disease. J. Crohns Colitis 2019; 13; 472-481.
Wen KW, Kim GE, Rabinovitch PS, et al. Diagnosis, risk stratification, and management of ampullary dysplasia by DNA flow cytometric analysis of paraffin-embedded tissue. Mod. Pathol. 2019; In press. https://doi.org/10.1038/s41379-019-0272-2.
Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry. International Society for Analytical Cytology. Cytometry 1993; 14; 472-477.
Rabinovitch PS. Practical considerations for DNA content and cell cycle analysis. In Bauer KD, Duque RE, Shankey TV eds. Clinical flow cytometry: principles and applications. Baltimore: Williams and Wilkins, 1992; 117-142.
Warrens MJ. Inequalities between multi-rater kappas. Adv. Data Anal. Classif. 2010; 4; 271-286.
Brennan RL, Prediger DJ. Coefficient kappa: some uses, misuses, and alternatives. Educ. Psychol. Meas. 1981; 41; 687-699.
Zhang X, Huang Q, Goyal RK, et al. DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's esophagus and associated neoplastic lesions. Am. J. Surg. Pathol. 2008; 32; 1327-1335.
Eaden J, Abrams K, McKay H, et al. Inter-observer variation between general and specialist gastrointestinal pathologists when grading dysplasia in ulcerative colitis. J. Pathol. 2001; 194; 152-157.
Dixon MF, Brown LJ, Gilmour HM, et al. Observer variation in the assessment of dysplasia in ulcerative colitis. Histopathology 1988; 13; 385-397.
Odze RD, Tomaszewski JE, Furth EE, et al. Variability in the diagnosis of dysplasia in ulcerative colitis by dynamic telepathology. Oncol. Rep. 2006; 16; 1123-1129.
Melville DM, Jass JR, Shepherd NA, et al. Dysplasia and deoxyribonucleic acid aneuploidy in the assessment of precancerous changes in chronic ulcerative colitis. Observer variation and correlations. Gastroenterology 1988; 95; 668-675.
Allende D, Elmessiry M, Hao W, et al. Inter-observer and intra-observer variability in the diagnosis of dysplasia in patients with inflammatory bowel disease: correlation of pathological and endoscopic findings. Colorect. Dis. 2014; 16; 710-718.
Rubin CE, Haggitt RC, Burmer GC, et al. DNA aneuploidy in colonic biopsies predicts future development of dysplasia in ulcerative colitis. Gastroenterology 1992; 103; 1611-1620.
Holzmann K, Weis-Klemm M, Klump B, et al. Comparison of flow cytometry and histology with mutational screening for p53 and Ki-ras mutations in surveillance of patients with long-standing ulcerative colitis. Scand. J. Gastroenterol. 2001; 36; 1320-1326.
Rutegård J, Ahsgren L, Stenling RDNA, et al. DNA content and mucosal dysplasia in ulcerative colitis. Flow cytometric analysis in patients with dysplastic or indefinite morphologic changes in the colorectal mucosa. Dis. Colon Rectum 1989; 32; 1055-1059.
Hartmann DP, Montgomery EA, Carr NJ, et al. Flow cytometric DNA analysis of ulcerative colitis using paraffin-embedded biopsy specimens: comparison with morphology and DNA analysis of fresh samples. Am. J. Gastroenterol. 1995; 90; 590-596.
Hammarberg C, Slezak P, Tribukait B. Early detection of malignancy in ulcerative colitis. A flow-cytometric DNA study. Cancer 1984; 53; 291-295.
Holzmann K, Klump B, Borchard F, et al. Comparative analysis of histology, DNA content, p53 and Ki-ras mutations in colectomy specimens with long-standing ulcerative colitis. Int. J. Cancer 1998; 76; 1-6.
Lindberg JO, Stenling RB, Rutegård JN. DNA aneuploidy as a marker of premalignancy in surveillance of patients with ulcerative colitis. Br. J. Surg. 1999; 86; 947-950.
Löfberg R, Caspersson T, Tribukait B, et al. Comparative DNA analyses in longstanding ulcerative colitis with aneuploidy. Gut 1989; 30; 1731-1736.
Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology 2010; 138; 738-745.
Van Assche G, Dignass A, Bokemeyer B, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J. Crohns Colitis 2013; 7; 1-33.
Bernstein CN, Shanahan F, Weinstein WM. Are we telling patients the truth about surveillance colonoscopy in ulcerative colitis? Lancet 1994; 343; 71-74.
Navaneethan U, Jegadeesan R, Gutierrez NG, et al. Progression of low-grade dysplasia to advanced neoplasia based on the location and morphology of dysplasia in ulcerative colitis patients with extensive colitis under colonoscopic surveillance. J. Crohns Colitis 2013; 7; e684-e691.
Ullman T, Croog V, Harpaz N, et al. Progression of flat low-grade dysplasia to advanced neoplasia in patients with ulcerative colitis. Gastroenterology 2003; 125; 1311-1319.
Reid BJ, Haggitt RC, Rubin CE, et al. Barrett’s esophagus. Correlation between flow cytometry and histology in detection of patients at risk for adenocarcinoma. Gastroenterology 1987; 93; 1-11.